PRTK Paratek Pharmaceuticals Inc.

7.34
+0.08  (+1%)
Previous Close 7.26
Open 7.32
52 Week Low 4.03
52 Week High 8.75
Market Cap $344,365,481
Shares 46,916,278
Float 45,362,825
Enterprise Value $464,653,201
Volume 149,715
Av. Daily Volume 431,257
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
Omadacycline - oral
Acute bacterial skin and skin structure infections (ABSSSI)
sNDA Filing
sNDA Filing
sNDA filing submitted July 2020.
Omadacycline
Complicated urinary tract infections (cUTI) / acute pyelonephritis
Phase 2
Phase 2
Phase 2 data released October 31, 2019. Comparable levels of clinical success but microbiological responses were generally lower than comparators.
Omadacycline
Urinary tract infections
Phase 2
Phase 2
Phase 2 data released October 31, 2019. Comparable levels of clinical success but microbiological responses were generally lower than comparators.
Omadacycline
Acute bacterial skin and skin structure infections (ABSSSI)
Approved
Approved
FDA Approval announced October 2, 2018.
Omadacycline
Community-acquired bacterial pneumonia (CABP)
Approved
Approved
FDA Approval announced October 2, 2018.
Sarecycline
Severe acne vulgaris
Approved
Approved
FDA Approval announced October 2, 2018.
Intermezzo
Insomnia
Approved
Approved
Approved November 23, 2011.

Latest News

  1. -- NUZYRA Generated Net U.S. Sales of $12.4 Million in the Fourth Quarter 2020; a 14% Increase Over the Third Quarter 2020

    -- NUZYRA Expansion into the Primary Care Setting in 2021

    -- Paratek Expects Full Year 2021 Total Revenue Between $166 and $177 Million

    BOSTON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today reported financial results and provided an update on corporate activities for the quarter and year ended December 31, 2020.

    "The launch of NUZYRA continued to demonstrate…

    -- NUZYRA Generated Net U.S. Sales of $12.4 Million in the Fourth Quarter 2020; a 14% Increase Over the Third Quarter 2020



    -- NUZYRA Expansion into the Primary Care Setting in 2021

    -- Paratek Expects Full Year 2021 Total Revenue Between $166 and $177 Million

    BOSTON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today reported financial results and provided an update on corporate activities for the quarter and year ended December 31, 2020.



    "The launch of NUZYRA continued to demonstrate consistent quarter-over-quarter growth through 2020 in a challenging environment created by the ongoing COVID-19 pandemic," said Evan Loh, M.D., Chief Executive Officer at Paratek. "The full year commercial net U.S. sales of NUZYRA, which landed at the high end of our guidance range, reflects the strong health of the underlying core commercial business. With two Biomedical Advanced Research and Development Authority (BARDA) Project BioShield procurements for the Strategic National Stockpile (SNS) now anticipated in 2021 plus the expected continued commercial growth of NUZYRA, we are anticipating a significant ramp up in total revenue for 2021. We believe prescribers recognize NUZYRA as an important life-saving antibiotic that addresses patient needs in the face of the growing global threat from antibiotic resistance."



    "In our conversations with clinicians over the past several years, it is clear there is a tremendous unmet need for a well-tolerated, once daily oral broad-spectrum antibiotic that includes coverage against MRSA for skin infections. Current generic antibiotic options are universally challenged by either significant bacterial resistance or serious safety concerns that limit their clinical utility," said Adam Woodrow, Paratek's President and Chief Commercial Officer. "NUZYRA's product profile makes it a very attractive treatment option for community use. With access now solidly established with the payers and significant support from infectious disease specialists, we believe our primary care expansion will accelerate and strengthen our sales trajectory, especially as we enter the second half of 2021."



    Key 2021 Priorities

    • Expansion of NUZYRA into Primary Care Setting: Paratek completed the hiring of approximately 40 U.S. sales representatives in February 2021 to enable the expansion of the NUZRYA launch into the primary care setting. The Company expects to execute this expansion within its previously communicated cash runway guidance.
    • NTM Rare Disease Opportunity: The Company plans to initiate a Phase 2b study, as early as mid-2021, to explore the potential utility of omadacycline as a treatment for non-tuberculous mycobacteria (NTM) infections due to Mycobacterium abscessus (M. abscessus), a rare disease with currently no approved therapies. M. abscessus and based on Company estimates represents a potential $1.0 billion addressable market opportunity in the U.S.
    • Continued Progress of the BARDA Project BioShield Anthrax Program: The Company expects to continue to execute and deliver on its contract with BARDA to develop NUZYRA for the treatment of pulmonary anthrax, a critical bioterrorism threat deemed important to national security by BARDA. These activities include advancing the U.S. onshoring of NUZYRA manufacturing and the continued execution of certain preclinical research activities supporting the pulmonary anthrax development program. Under Paratek's five-year agreement with BARDA, the Company also anticipates two procurements of 2,500 treatment courses of NUZYRA each in 2021 for addition to the SNS.

    Other Recent Highlights

    • In December 2020, Paratek entered into a $60 million non-recourse loan agreement with an affiliate of R-Bridge Healthcare Investment Advisory (the R-Bridge Loan) that will be repaid using (i) all proceeds of royalties from the Company's License and Collaboration Agreement with Zai Lab and (ii) an initial 2.5% revenue interest from the Company's U.S. net sales of NUZYRA (initial annual cap of $10 million).
      • The net proceeds of the R-Bridge Loan, together with cash on hand, was used to prepay in full all obligations outstanding under the Company's Amended and Restated Loan and Security Agreement with Hercules Capital on December 31, 2020.

    Fourth Quarter and Full Year 2020 Financial Results

    • Fourth quarter 2020 revenue
      • Total revenue was $16.0 million for the fourth quarter of 2020, an increase of 17% over the third quarter of 2020 and an increase of 78% over the fourth quarter of 2019.   
      • NUZYRA generated $12.4 million in net U.S. sales during the fourth quarter of 2020, an increase of 14% over the third quarter of 2020 and an increase of 130% over the fourth quarter of 2019.   
      • Government contract service and grant revenue was $2.8 million for the fourth quarter of 2020 versus $2.7 million in the third quarter of 2020.  No revenue was generated from the BARDA contract in 2019 as it was executed in December of that year. 
    • Full year 2020 total revenue 
      • Full year 2020 total revenue was $46.9 million, an increase of 184% over full year 2019 total revenue.   
      • NUZYRA generated $38.8 million in net U.S. sales for the full year 2020, an increase of 237% over the full year 2019.
        • The growth in NUZYRA sales in 2020 reflects the Company's continued commitment to strong execution and NUZYRA's attributes that address unmet needs in the marketplace despite the significant disruptions of patient traffic to physician offices and institutions throughout the ongoing COVID-19 pandemic.
        • In today's COVID-19 environment, NUZYRA's ability to minimize hospital stays with the oral formulation is especially relevant for many prescribers and a meaningful benefit for patients.
      • Government contract service and grant revenue was $6.7 million in 2020.  No revenue was generated from the BARDA contract in 2019 as it was executed in December of that year. 
      • Collaboration and royalty revenue of $1.5 million in 2020 is primarily comprised of royalties earned from SEYSARA® sales in the U.S. Collaboration and royalty revenue of $5.0 million in 2019 included a $3.0 million milestone earned from Zai Lab in addition to royalties earned from SEYSARA sales in the U.S.

    Research and development (R&D) expenses were $6.3 million for the fourth quarter of 2020, compared to $9.1 million for same period in the prior year. R&D expenses were $23.9 million for the full year 2020, compared to $39.6 million in the prior year. The decrease in both periods is primarily the result of lower clinical study costs associated with completion of the Phase 2 UTI program in 2019, partially offset by an increase in expenses incurred under the BARDA contract and third-party manufacturing process scale-up to meet expected future demand for NUZYRA. 



    Selling, general and administrative (SG&A) expenses were $24.3 million for the fourth quarter of 2020, compared to $21.3 million for the same period in the prior year.  The $3.0 million increase is primarily due to costs incurred to realign our hospital territories and our community expansion. 



    SG&A expenses were $89.9 million for the full year 2020, compared to $89.1 million in the prior year.  The $0.8 million increase is primarily the result of costs for the Company's contract sales organization and higher product distribution fees, partially offset by lower marketing and promotional program expenses, personnel-related costs and travel due to the COVID-19 pandemic.



    Paratek reported a net loss of $25.0 million, or ($0.54) per share, for the fourth quarter of 2020, compared to a net loss of $27.4 million, or ($0.81) per share, for the same period in 2019. 



    Paratek reported a net loss of $96.5 million, or ($2.19) per share, for the full year 2020 compared to a net loss of $128.8 million, or ($3.93) per share, for the same period in 2019. 



    Financial Guidance 

    Paratek also announced its full year 2021 financial guidance.

    • Paratek estimates 2021 total revenue in the range of $166 to $177 million. This range includes the following components:
      • 2021 NUZYRA net U.S. product sales are expected to be approximately $138 to $144 million, which includes:
        • U.S. net product sales between $62 to $68 million from the core commercial business
        • Two SNS procurements by BARDA valued at approximately $76 million
      • Royalty and collaboration revenue of approximately $8 million
      • BARDA government contract service and grant revenue between $20 to $25 million
        • BARDA contract service and grant revenue consists of reimbursement of NUZYRA post-marketing requirements, the anthrax development program and the U.S. onshoring of NUZYRA manufacturing
    • Paratek estimates 2021 R&D and SG&A expense to be approximately $150 to $155 million. This range includes the following components:
      • Core business R&D and SG&A expense of $130 million, an increase of 20% over 2020 but consistent with 2019 pre-pandemic levels
        • The expected increase in R&D and SG&A expense in 2021 when compared to 2020 will be driven by costs associated with the primary care expansion and the initiation of the phase 2b study in NTM
      • BARDA R&D and U.S. onshoring cost reimbursements between $20 to $25 million
    • Based upon the Company's current operating plan as described above, Paratek anticipates its existing cash, cash equivalents and marketable securities of $125.2 million as of December 31, 2020, provide for a cash runway through the end of 2023 with a pathway to cash flow break even.

    Company performance and unanticipated events could cause actual results to vary from this forward-looking guidance. 



    Call and Webcast

    Paratek's earnings conference call for the quarter and year ended December 31, 2020 will be broadcast at 4:30 p.m. EST on February 24, 2021. The live audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of Paratek's website at www.ParatekPharma.com.



    Domestic investors wishing to participate in the call should dial: 877-407-0792 and international investors should dial: 201-689-8263. The conference ID is 13716761. Investors can also access the call at http://public.viavid.com/index.php?id=143647.



    Website Information

    Paratek routinely posts important information for investors on the Investor Relations section of its website at www.ParatekPharma.com. Paratek intends to use this website as a means of disclosing material, non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of Paratek's website, in addition to following its press releases, U.S. Securities and Exchange Commission (SEC) filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Paratek's website is not incorporated by reference into, and is not a part of, this document.



    About Paratek Pharmaceuticals, Inc.

    Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.



    The Company's lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the U.S. for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.



    Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC (Almirall). Paratek retains the development and commercialization rights for sarecycline in the rest of the world.



    In 2019, Paratek was awarded a contract from BARDA, valued at ~$285 million, to support the development and U.S.-based manufacturing of NUZYRA for the treatment of pulmonary anthrax.



    For more information, visit www.ParatekPharma.com or follow @ParatekPharma on Twitter.



    About NUZYRA®

    NUZYRA (omadacycline) is a novel antibiotic with both once-daily oral and intravenous formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). A modernized tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and other drug-resistant strains.



    Please see full Prescribing Information for NUZYRA at www.NUZYRA.com.



    Forward Looking Statements 

    This press release contains forward-looking statements including statements related to our overall strategy, products, prospects, potential and expected results, including statements about the impact of the COVID-19 pandemic on our revenue projections, access to hospital institutions, supply chain and clinical trials, projected awareness, payor coverage, net product revenues, total revenues including assumptions related to our financial guidance, the financial impact of our BARDA contract including the status of the FDA review of the pre-EUA submission, the exercise and timing of BARDA's procurement of NUZYRA for the SNS, BARDA exercising full contract line items, including for U.S. onshoring and PMR reimbursement, our anticipated cash runway, our operating expenses, our R-Bridge loan secured by our Zai Labs royalties and a NUZYRA synthetic royalty, our SEYSARA royalties and SEYSARA-backed loan, the strategy, execution and progression of our commercial launch of NUZYRA, our ability to shape the future treatment paradigm for community-acquired pneumonia and serious skin infections, our plans to evaluate additional indications for NUZYRA, including NTM, and to work toward an oral-only indication in CABP, future governmental stockpiling opportunities, and our potential to further drive long-term value for all of our shareholders.  All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "expect," "look forward," "anticipate," "continue," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties.  We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements.  Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties.  These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2019 and our other filings with the Securities and Exchange Commission.  We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.



    PARATEK PHARMACEUTICALS, INC.

    Condensed Consolidated Balance Sheets

    (unaudited)

    (in thousands)

      As of December 31,
       2020   2019 
    Cash, cash equivalents and marketable securities $125,162  $215,379 
    Total assets  176,853   251,079 
    Working capital  140,164   219,154 
    Total current liabilities  23,953   24,200 
    Long-term debt  250,474   260,728 
    Common stock and additional paid-in capital  705,535   671,537 
    Accumulated deficit  (807,799)  (711,258)
    Total stockholders' deficit  (102,260)  (39,647)





    Condensed Consolidated Statements of Operations


    (unaudited)

    (in thousands, except loss per share data)

      Three Months Ended December 31,  Year Ended December 31, 
      2020  2019  2020  2019 
    Product revenue, net $12,422  $5,415  $38,753  $11,517 
    Government contract service revenue  1,739      3,299    
    Government contract grant revenue  1,103      3,407    
    Collaboration and royalty revenue  755   3,552   1,465   5,027 
    Net revenue  16,019   8,967   46,924   16,544 
    Expenses:                
    Cost of product revenue  2,925   1,755   8,651   3,484 
    Research and development  6,286   9,133   23,922   39,554 
    Selling, general and administrative  24,341   21,261   89,855   89,135 
    Total operating expenses  33,552   32,149   122,428   132,173 
    Loss from operations  (17,533)  (23,182)  (75,504)  (115,629)
    Other income and expenses:                
    Interest income  167   739   1,515   3,574 
    Interest expense  (5,265)  (4,626)  (20,240)  (16,403)
    Loss on extinguishment of debt  (2,368)     (2,368)   
    Other gains (losses), net  (11)  5   56   (31)
    Net loss before provision for income taxes  (25,010)  (27,064)  (96,541)  (128,489)
    Provision for income taxes     301      301 
    Net loss attributable to common stockholders $(25,010) $(27,365) $(96,541) $(128,790)
    Net loss per share attributable to common stockholders:                
    Basic and diluted net loss per common share $(0.54) $(0.81) $(2.19) $(3.93)
    Weighted average common shares outstanding                
    Basic and diluted  45,911,211   33,789,704   44,174,765   32,791,934 

    CONTACT:

       
    Investor and Media Relations:   
    Ben Strain   
    617-807-6688   
       





    Primary Logo

    View Full Article Hide Full Article
  2. BOSTON, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the Company will present at the 10th Annual SVB Leerink Global Healthcare Conference which will be held Thursday, February 25, 2021 at 11:20 a.m. ET.

    To access the live webcast of Paratek's presentation, please visit https://wsw.com/webcast/svbleerink47/prtk/2689024.

    Please connect to the web site at least 15 minutes prior to the live presentation to ensure adequate time for any software…

    BOSTON, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the Company will present at the 10th Annual SVB Leerink Global Healthcare Conference which will be held Thursday, February 25, 2021 at 11:20 a.m. ET.

    To access the live webcast of Paratek's presentation, please visit https://wsw.com/webcast/svbleerink47/prtk/2689024.

    Please connect to the web site at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast can be accessed for up to 90 days following the live presentation.

    About Paratek Pharmaceuticals, Inc.

    Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.



    The Company's lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the U.S. for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.



    Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC (Almirall). Paratek retains the development and commercialization rights for sarecycline in the rest of the world.



    In 2019, Paratek was awarded a contract from BARDA, valued at ~$285 million, to support the development and U.S.-based manufacturing of NUZYRA for the treatment of pulmonary anthrax.



    For more information, visit www.ParatekPharma.com or follow @ParatekPharma on Twitter.



    Forward Looking Statements 

    This press release contains forward-looking statements including statements related to our overall strategy, products, prospects and potential.  All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "expect," "look forward," "anticipate," "continue," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties.  We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements.  Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties.  These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2019 and our other filings with the Securities and Exchange Commission.  We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

    CONTACT:

    Investor and Media Relations:

    Ben Strain

    617-807-6688

     



    Primary Logo

    View Full Article Hide Full Article
  3. BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced the Company will host a conference call and live audio webcast on Wednesday, February 24, 2021 at 4:30 p.m. EST to report its financial results for the quarter and full year ended December 31, 2020 and provide a corporate update.

    The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com.

    Domestic investors wishing to participate…

    BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced the Company will host a conference call and live audio webcast on Wednesday, February 24, 2021 at 4:30 p.m. EST to report its financial results for the quarter and full year ended December 31, 2020 and provide a corporate update.



    The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com.



    Domestic investors wishing to participate in the call should dial: 877-407-0792 and international investors should dial: 201-689-8263. The conference ID is 13716761. Investors can also access the call at http://public.viavid.com/index.php?id=143647.



    About Paratek Pharmaceuticals, Inc.

    Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.



    The Company's lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the U.S. for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.



    Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC (Almirall). Paratek retains the development and commercialization rights for sarecycline in the rest of the world.



    In 2019, Paratek was awarded a contract from BARDA, valued at ~$285 million, to support the development and U.S.-based manufacturing of NUZYRA for the treatment of pulmonary anthrax.



    For more information, visit www.ParatekPharma.com or follow @ParatekPharma on Twitter.



    About NUZYRA®

    NUZYRA (omadacycline) is a novel antibiotic with both once-daily oral and intravenous formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). A modernized tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and other drug-resistant strains.



    Please see full Prescribing Information for NUZYRA at www.NUZYRA.com.



    Forward Looking Statements

    This press release contains forward-looking statements including statements related to our overall strategy, products, prospects and potential. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "expect," "look forward," "anticipate," "continue," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties. These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2019 and our other filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

    CONTACT:

    Investor and Media Relations:

    Ben Strain

    617-807-6688

     



    Primary Logo

    View Full Article Hide Full Article
  4. BOSTON, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a biopharmaceutical company that develops and commercializes life-saving therapies for public health threats in the community, hospital, and military settings, today announced the expansion of the Company's commercial promotion of NUZYRA® (omadacycline) into the community setting, building on the successful launch of NUZYRA in the hospital environment.

    The revenue trajectory of the ongoing NUZYRA commercial launch has exceeded that of other antibiotics launched in the last five years. Based on NUZYRA's product attributes, including its once-daily oral formulation, and broad reimbursement coverage secured to date, Paratek has initiated efforts to expand…

    BOSTON, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a biopharmaceutical company that develops and commercializes life-saving therapies for public health threats in the community, hospital, and military settings, today announced the expansion of the Company's commercial promotion of NUZYRA® (omadacycline) into the community setting, building on the successful launch of NUZYRA in the hospital environment.

    The revenue trajectory of the ongoing NUZYRA commercial launch has exceeded that of other antibiotics launched in the last five years. Based on NUZYRA's product attributes, including its once-daily oral formulation, and broad reimbursement coverage secured to date, Paratek has initiated efforts to expand NUZYRA's commercial promotion into the community setting. NUZYRA's once-daily IV and oral treatment option, which is approved for both community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), fills a critical gap today at a time when it is essential to keep patients out of the hospital during the ongoing COVID-19 pandemic. The Company's expansion of commercial promotion in the community setting will focus on ABSSSI, with a plan to broaden to include CABP after the anticipated approval of the oral-only loading-dose regimen for CABP, which is expected during the second quarter of 2021.

    "In our conversations with clinicians over the past several years, it is clear there is a tremendous unmet need for a new, safe, well-tolerated and effective broad-spectrum once-daily oral antibiotic in the community setting. The existing older-generation agents are universally challenged by either significant resistance concerns that limit their utility or serious safety concerns," said Adam Woodrow, President and Chief Commercial Officer at Paratek. "NUZYRA's product profile makes it a very attractive option for community use, and with reimbursement access now solidly established, combined with significant support from infectious disease specialists who have been using NUZYRA successfully since its launch in early 2019, we believe we can successfully continue to strengthen our launch trajectory, especially as we enter the second half of 2021."

    To support the launch of NUZRYA into the community setting, Paratek has initiated the hiring of approximately 40 U.S. community-based sales representatives, which will complement its established and successful hospital-based sales organization. Upon completion of the current community-based expansion, Paratek anticipates having a sales force to address both the community and hospital settings of approximately 90-100 customer facing representatives. The Company expects to execute this expansion within its previously communicated cash runway guidance. The expansion of the sales organization builds upon a focused and targeted community sales pilot program conducted in the second half of 2020. The data provided by the pilot suggest NUZYRA has an opportunity to address significant unmet needs in the community setting through building awareness among primary care physicians, leading to meaningful trial and adoption with positive patient outcomes. Paratek expects to accomplish this initial phase of the community expansion within the first quarter of 2021.

    "Every other sector of the pharmaceutical armamentarium has added new, more effective and better tolerated treatment options over the past 20 years while the community antibiotic segment has gone in the other direction, where our choice of treatments has become ever more limited because of a lack of innovation and overwhelming resistance. This shift significantly increases risks to patients," said Dr. Susan Butler-Sumner, a family medicine physician practicing in the community setting for more than 40 years. "Universally, community-based clinicians in the U.S. are looking for new antibiotic treatment options, particularly safe, well-tolerated and effective once-daily oral options with an accompanying IV formulation if needed. I believe NUZYRA will be able to significantly help address this clinically important treatment gap."

    About Paratek Pharmaceuticals, Inc.

    Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.

    The Company's lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the U.S. for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.

    Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC (Almirall). Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

    In 2019, Paratek was awarded a contract from BARDA, valued at ~$285 million, to support the development and U.S.-based manufacturing of NUZYRA for the treatment of pulmonary anthrax.

    For more information, visit www.ParatekPharma.com or follow @ParatekPharma on Twitter.

    About NUZYRA

    NUZYRA (omadacycline) is a novel antibiotic with both once-daily oral and intravenous (IV) formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). A modernized tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and other drug-resistant strains.

    Indications and Usage

    NUZYRA is a tetracycline class antibacterial indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms:

    Community-Acquired Bacterial Pneumonia (CABP) caused by the following: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.

    Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by the following: Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Staphylococcus lugdunensis, Streptococcus pyogenes, Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Enterococcus faecalis, Enterobacter cloacae, and Klebsiella pneumoniae. 

    Usage

    To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA and other antibacterial drugs, NUZYRA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

    Important Safety Information

    Contraindications

    NUZYRA is contraindicated in patients with known hypersensitivity to omadacycline or tetracycline class antibacterial drugs, or to any of the excipients.

    Warnings and Precautions

    Mortality imbalance was observed in the CABP clinical trial with eight deaths (2%) occurring in patients treated with NUZYRA compared to four deaths (1%) in patients treated with moxifloxacin. The cause of the mortality imbalance has not been established. All deaths, in both treatment arms, occurred in patients > 65 years of age; most patients had multiple comorbidities. The causes of death varied and included worsening and/or complications of infection and underlying conditions. Closely monitor clinical response to therapy in CABP patients, particularly in those at higher risk for mortality.

    The use of NUZYRA during tooth development (last half of pregnancy, infancy and childhood to the age of eight years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia.

    The use of NUZYRA during the second and third trimester of pregnancy, infancy and childhood up to the age of eight years may cause reversible inhibition of bone growth.

    Hypersensitivity reactions have been reported with NUZYRA. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with other tetracycline-class antibacterial drugs. NUZYRA is structurally similar to other tetracycline-class antibacterial drugs and is contraindicated in patients with known hypersensitivity to tetracycline-class antibacterial drugs. Discontinue NUZYRA if an allergic reaction occurs.

    Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs.

    NUZYRA is structurally similar to tetracycline-class of antibacterial drugs and may have similar adverse reactions. Adverse reactions including photosensitivity, pseudotumor cerebri, and anti-anabolic action which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests, have been reported for other tetracycline-class antibacterial drugs, and may occur with NUZYRA. Discontinue NUZYRA if any of these adverse reactions are suspected.

    Prescribing NUZYRA in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

    Adverse Reactions

    The most common adverse reactions (incidence ≥2%) are nausea, vomiting, infusion site reactions, alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyl transferase increased, hypertension, headache, diarrhea, insomnia, and constipation.

    Drug Interactions

    Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage while taking NUZYRA.

    Absorption of tetracyclines, including NUZYRA is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron containing preparations.

    Use in Specific Populations

    Lactation: Breastfeeding is not recommended during treatment with NUZYRA.

    To report SUSPECTED ADVERSE REACTIONS, contact Paratek Pharmaceuticals, Inc. at 1-833-727-2835 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    Please see full Prescribing Information for NUZYRA at www.NUZYRA.com.

    Forward Looking Statements 

    This press release contains forward-looking statements including statements related to our overall strategy, products, prospects, potential and expected results, including statements about the timing, size and scope of our Community based product launch and community and hospital-based field forces, cash runway expectations and the impact of the COVID-19 pandemic on our business. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "expect," "look forward," "anticipate," "continue," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties. These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2019 and our other filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

    CONTACT:

    Investor and Media Relations:
    Ben Strain
    617-807-6688



    Primary Logo

    View Full Article Hide Full Article
  5. BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the Company will present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference which will be broadcast starting on Monday, January 11, 2021 at 6:00 a.m. ET.

    To access the live webcast of Paratek's presentation, please visit https://journey.ct.events/view/f3b52f49-bcd0-4072-bdc0-942d1d5937d0.

    Please connect to the web site at least 15 minutes prior to the live presentation to ensure adequate time for any…

    BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the Company will present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference which will be broadcast starting on Monday, January 11, 2021 at 6:00 a.m. ET.

    To access the live webcast of Paratek's presentation, please visit https://journey.ct.events/view/f3b52f49-bcd0-4072-bdc0-942d1d5937d0.

    Please connect to the web site at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast can be accessed for up to 90 days following the live presentation.

    About Paratek Pharmaceuticals, Inc.

    Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.

    The Company's lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the U.S. for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.

    Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC (Almirall). Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

    In 2019, Paratek was awarded a five-year contract from the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $285 million, with an option to extend to ten years, to support the development of NUZYRA for the treatment of pulmonary anthrax, FDA post-marketing requirements (PMR) associated with the initial NUZYRA approval, and the option to procure up to 10,000 treatment courses of NUZYRA for the Strategic National Stockpile (SNS) for use against potential biothreats.

    For more information, visit www.ParatekPharma.com or follow @ParatekPharma on Twitter.

    Forward Looking Statements 

    This press release contains forward-looking statements including statements related to our overall strategy, products, prospects and potential.  All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "expect," "look forward," "anticipate," "continue," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties.  We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements.  Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties.  These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2019 and our other filings with the Securities and Exchange Commission.  We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

    CONTACT:

    Investor and Media Relations:
    Ben Strain
    617-807-6688


    Primary Logo

    View Full Article Hide Full Article
View All Paratek Pharmaceuticals Inc. News